Golden Star Resources Ltd. (GSS)
NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
3.8100+0.1500 (+4.10%)
At close: 1:00PM EST
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 3.6600 |
| Open | 3.6900 |
| Bid | 3.6000 x 1400 |
| Ask | 3.9000 x 1200 |
| Day's Range | 3.5600 - 3.8300 |
| 52 Week Range | 1.8500 - 5.2000 |
| Volume | 219,850 |
| Avg. Volume | 374,601 |
| Market Cap | 420.376M |
| Beta (5Y Monthly) | 0.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1030 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.07 |
- Zacks
Golden Star Resources (GSS) Q3 Earnings Beat Estimates
Golden Star (GSS) delivered earnings and revenue surprises of 14.29% and -23.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
- CNW Group
Golden Star Resources Reports Results for the Three and Nine Months Ended September 30, 2020
Operational Delivery Continues as Prestea Sale Unlocks Investment CapacityTORONTO, Oct. 28, 2020 /CNW/ - Golden Star Resources Ltd.
- CNW Group
New laboratory development can speed up validation of effectiveness for potential COVID-19 treatments
Lab-made 'replicons' enable testing of new drug therapies in a rapid and safe processLONDON, ON, Oct. 15, 2020 /CNW/ - Fanshawe College's Centre for Research and Innovation has developed a safe, rapid and inexpensive method to identify the effectiveness of potential COVID-19 drug treatments.
© 2020 Verizon Media. All rights reserved.
